- POSITIVE
Annual Revenue Mahamaya Lifesciences Mar-2026 Annual Revenue is Rs 330 Cr which is growth of 23.5% YoY.
- POSITIVE
Annual Net Profit Mahamaya Lifesciences Mar-2026 Annual Net Profit is Rs 17 Cr which is growth of 28.9% YoY.
Mahamaya Lifesciences was incorporated on May 07, 2002. The company manufactures and supplies pesticide formulations to Indian agrochemical firms and multinational corporations. It initially focused on importing and registering key pesticide molecules with the CIBRC, later marketing them as both technical products and value-added formulations for domestic and global clients
| Bidding Dates |
|---|
| 11 Nov 2025 - 13 Nov 2025 |
| Subscription |
|---|
| 1.59x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹259,200 | 2 | 2 | 1200 | 6.2 M | ₹108 - ₹114 | 56.35 % | ₹667.3 M - ₹704.4 M | RHP DOC |
Mahamaya Lifesciences IPO SUBSCRIPTION STATUS
13 Nov '25Total1.59x
Retail Individual Investor1.36x
HNI (NII) Investors5.29x
Qualified Institutional Buyers0.63x
Mahamaya Lifesciences IPO overall subscription rate was 1.59 times the total available shares
Mahamaya Lifesciences IPO retail subscription rate was 1.36 times in the retail segment
Mahamaya Lifesciences IPO non-institutional investor subscription rate was 5.29 times in the non-institutional investor category
Mahamaya Lifesciences IPO Qualified Institutional Bidder subscription rate was 0.63 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
13 Nov 2025 (Day 3) | 1.36x | 5.29x | 0.63x |
12 Nov 2025 (Day 2) | 0.27x | 0.83x | 0.34x |
11 Nov 2025 (Day 1) | 0.1x | 0.47x | 0x |
Mahamaya Lifesciences FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| Q1FY26 | 83.0 | 4.1 | 1.4 | 1.2 | 9.6% |
| FY25 | 264.1 | 12.9 | 0.5 | -8.0 | 9.2% |
| FY24 | 161.6 | 5.2 | -22.7 | -25.0 | 8.2% |
| FY23 | 137.1 | 3.8 | 1.1 | -1.8 | 6.5% |
Mahamaya Lifesciences IPO SUBSCRIPTION STATUS DETAILS
Mahamaya Lifesciences had 6.2 M shares on offer
Mahamaya Lifesciences IPO offer price was in the range ₹108 - ₹114
Mahamaya Lifesciences IPO minimum Investment was ₹259200
Mahamaya Lifesciences IPO issue size was ₹ 667.3 M - ₹ 704.4 M
Mahamaya Lifesciences had a minimum lot size of 1200 Shares per application
Mahamaya Lifesciences NUMBER OF SHARES ON OFFER
Total6.2 M
Fresh Issue5.6 M
Offer for Sale540.0 K
Post Issue Promoter Holding %56.35 %
Mahamaya Lifesciences IPO IMPORTANT DATES
| Issue Open Date | 11 Nov 2025 |
| Issue close Date | 13 Nov 2025 |
| Allotment Date | 14 Nov 2025 |
| Refund Date | 17 Nov 2025 |
| Demat Account Credit Date | 17 Nov 2025 |
| Listing Date | 18 Nov 2025 |
| Listing on Exchange(s) | BSE |
| Mahamaya Lifesciences Allotment Status | Exchange/ Registrar |
Mahamaya Lifesciences IPO subscription opened on 11 Nov 2025, and closed on 13 Nov 2025
IPO allotment for Mahamaya Lifesciences was finalized on Friday, 14 Nov 2025
IPO listing for Mahamaya Lifesciences was on BSE on Tuesday, 18 Nov 2025
Mahamaya Lifesciences IPO LISTING GAINS
| Issue Price (adjusted) | 114.0 |
| Listing Open Price | 116.0 |
| Listing Close Price | 116.0 |
| Listing Gain% | 1.8% |
| Current Gain% | 52.8% |
Mahamaya Lifesciences Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mahamaya Lifesciences Ltd. | 174.2 | 407.7 | 24.4 | 0.8 | 1.2 | 13.7 | 5.4 | 330 | 23.5 | 16.7 | 29.2 | 7.1 | 29.2 |
| UPL Ltd. | 488.4 | 41233.4 | 21.4 | 0.3 | 0.8 | 5.5 | 2 | 52502 | 11.4 | 1922 | 114.3 | 22.8 | 61.5 |
| PI Industries Ltd. | 2118.2 | 32136.9 | 27.6 | -1 | 4.9 | 11.8 | 9.8 | 7024.4 | -15.6 | 1320.8 | -20.4 | 76.8 | -27.7 |
| Sumitomo Chemical India Ltd. | 417.3 | 20829.4 | 35.9 | 9 | 6.4 | 16 | 12.1 | 3385 | 3.6 | 543 | 7.4 | 11.6 | 4 |
| Bayer Cropscience Ltd. | 3492 | 15693.8 | 21.4 | 0.9 | 2.8 | 23.2 | 12.1 | 5770 | 3.2 | 689.2 | 21.3 | 162.9 | 23.6 |
| Sharda Cropchem Ltd. | 723.9 | 6531.1 | 10.4 | 0.2 | 1.2 | 21.7 | 11.8 | 5409.8 | 23.5 | 680.9 | 123.7 | 69.4 | 49.1 |
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Mahamaya Lifesciences annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|---|---|
33.9% | 330 | 267.2 | 162.8 | 137.4 | 90.1 | ||
Operating Exp. Ann. | 32.1% | 295.8 | 241.2 | 148.2 | 128.2 | 83.8 | |
Operating Profit Ann. | 55% | 33.5 | 24.6 | 13.5 | 9 | 6.1 | |
OPM Ann. % | 15.9% | 10.16% | 9.19% | 8.27% | 6.52% | 6.77% | |
32.3% | 306.2 | 249.8 | 155.3 | 132.2 | 86.1 | ||
EBITDA Ann. | 55.1% | 34.3 | 26 | 14.7 | 9.2 | 6.3 | |
EBITDA Ann. margin % | 15.9% | 10.38% | 9.72% | 9.01% | 6.66% | 6.95% | |
Interest Ann. | 46.1% | 8.1 | 6.8 | 5.7 | 2.6 | 1.4 | |
Depr. | 19.2% | 2.2 | 1.8 | 1.4 | 1.3 | 0.9 | |
PBT Ann. | 66.3% | 23.9 | 17.4 | 7.5 | 5.2 | 4 | |
Tax Ann. | 70.2% | 7.4 | 4.4 | 2.1 | 1.5 | 1.1 | |
64.6% | 16.5 | 12.9 | 5.5 | 3.7 | 2.8 | ||
Net Profit Ann. | 64.6% | 16.5 | 12.8 | 5.5 | 3.7 | 2.8 | |
NPM Ann. % | 22.7% | 5.01% | 4.82% | 3.38% | 2.71% | 3.11% | |
EPS Adj. latest Ann. | 64.3% | 7.1 | 5.5 | 2.3 | 1.6 | 1.2 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
23.5%
2Y CAGR
42.4%
3Y CAGR
33.9%
Net Profit Ann.
1Y CHG
28.9%
2Y CAGR
73.2%
3Y CAGR
64.6%
Operating Exp. Ann.
1Y CHG
22.6%
2Y CAGR
41.3%
3Y CAGR
32.1%
Mahamaya Lifesciences INFORMATION ON IPO ISSUE
About Mahamaya Lifesciences
Mahamaya Lifesciences was incorporated on May 07, 2002. The company manufactures and supplies pesticide formulations to Indian agrochemical firms and multinational corporations. It initially focused on importing and registering key pesticide molecules with the CIBRC, later marketing them as both technical products and value-added formulations for domestic and global clients
Object of the Issue
- Purchase of equipment for the existing Formulation plant
- Funding capital expenditure towards setting up a new technical manufacturing plant
- Construction of a warehouse building and purchase of machinery
- Funding the working capital requirement of the company
- General corporate purposes
Mahamaya Lifesciences - PROMOTERS
| Name |
|---|
| Krishnamurthy Ganesan |
| Lalitha Krishnamurthy |
| Prashant Krishnamurthy |
Mahamaya Lifesciences - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Krishnamurthy Ganesan | Managing Director |
| Prashant Krishnamurthy | Executive Director & CFO |
| Lalitha Krishnamurthy | Whole-time Director |
| Charudatta Digambar Mayee | Independent Director |
| Gopal Krishna Raju | Independent Director |
| Sekhar Kavasseri Rajagopalan | Independent Director |
Mahamaya Lifesciences Lead Manager to the issue
Oneview Corporate Advisors Pvt. Ltd.
mbd@oneviewadvisors.com
Mahamaya Lifesciences Registrar to the issue
KFin Technologies Limited
compliance.corp@kfintech.com
Mahamaya Lifesciences Strengths
Diverse product portfolio
The company markets its products across India under well-established brands recognised by farmers. It drives demand through advertising, farmer interactions, field demonstrations, and distributor partnerships. As of June 30, 2025, its portfolio includes 136 insecticides, 71 fungicides, 58 herbicides, and several bio-stimulants, biopesticides, and biofertilisers
Strength
Sustainability through innovative approaches
The company aims to set new benchmarks in the crop protection industry by promoting farmer-friendly pesticide use and improving productivity. It focuses on manufacturing, registering, and exporting high-quality crop protection and bioproducts that enhance crop and soil health for better yields
Strength
Export opportunities
Over the past decade, the company has invested in registering its products globally and currently holds active registrations in countries such as the Dominican Republic, Egypt, Ethiopia, Jordan, the UAE, and Turkey. By generating data usable across multiple markets and participating in major international exhibitions, it aims to strengthen partnerships and expand export opportunities
Strength
Mahamaya Lifesciences Risks
Health & safety risks
The company’s operations are governed by strict environmental and worker safety laws, including the Environment Act, Air Act, and Water Act. Compliance with these regulations may require significant costs, and any non-compliance or incident could lead to material liabilities, adversely affecting its business and financial performance
Risk
Non-compliance risks
The company’s products are subject to government sample checks for quality verification. Any deviation from prescribed standards or packaging disclosures could lead to notices, suspension, or sales bans, adversely impacting revenue. However, the company follows stringent quality control and assurance processes to ensure full regulatory compliance
Risk
Counterfiet risks
The company faces risks from counterfeit products that imitate its genuine offerings, potentially damaging its brand reputation and reducing sales. These fake products may be less effective or harmful, leading to customer distrust and negatively impacting the company’s business, financial performance, and market credibility
Risk
IPO FAQs
This IPO consists of an offer for sale of up to Rs 6.2 crore, of 540,000 shares. It also consists of a fresh issue of Rs 64.3 crore.
The promoters of the company are Krishnamurthy Ganesan, Lalitha Krishnamurthy and Prashant Krishnamurthy.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 108.0 - 114.0.
The IPO application opens on Nov 11, 2025 and closes on Nov 13, 2025.
The minimum lot size for the IPO is 2400. The maximum lot size for the IPO is 2400.
For all category investors, the minimum application amount for this IPO is Rs. 259,200.0, the maximum value for this IPO is Rs 273,600.0.
This IPO will be allotted on Nov 14, 2025.
The refund will be credited to your account on Nov 17, 2025.
The allotted shares will be credited to your demat on Nov 17, 2025.
Mahamaya Lifesciences Ltd.’s shares listed on the stock exchanges on Nov 18, 2025.